Cantor Fitzgerald Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price

Eli Lilly and Company (NYSE:LLY) had its price target boosted by Cantor Fitzgerald from $985.00 to $1,205.00 in a note issued to investors on Thursday,Benzinga reports. The firm currently has an “overweight” rating on the stock. Cantor Fitzgerald’s price objective indicates a potential upside of 16.42% from the company’s current price.

Several other research firms have also recently weighed in on LLY. The Goldman Sachs Group set a $1,260.00 target price on Eli Lilly and Company in a research note on Thursday. Wall Street Zen lowered shares of Eli Lilly and Company from a “strong-buy” rating to a “buy” rating in a research note on Saturday, January 31st. Zacks Research cut Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research report on Friday, January 30th. Rothschild & Co Redburn upped their price target on shares of Eli Lilly and Company from $775.00 to $830.00 and gave the company a “neutral” rating in a report on Monday, January 26th. Finally, Deutsche Bank Aktiengesellschaft boosted their target price on shares of Eli Lilly and Company from $1,000.00 to $1,200.00 and gave the stock a “buy” rating in a research report on Wednesday, December 17th. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and an average price target of $1,194.92.

Eli Lilly and Company Trading Down 6.5%

Shares of NYSE LLY traded down $72.08 during mid-day trading on Thursday, hitting $1,035.05. 4,186,103 shares of the company traded hands, compared to its average volume of 3,269,749. The company has a quick ratio of 1.24, a current ratio of 1.55 and a debt-to-equity ratio of 1.71. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $1,133.95. The stock has a market capitalization of $978.51 billion, a price-to-earnings ratio of 50.68, a PEG ratio of 0.76 and a beta of 0.39. The business has a 50 day moving average of $1,054.31 and a two-hundred day moving average of $895.30.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Wednesday, February 4th. The company reported $7.54 EPS for the quarter, beating analysts’ consensus estimates of $7.48 by $0.06. The company had revenue of $19.29 billion during the quarter, compared to analyst estimates of $17.85 billion. Eli Lilly and Company had a net margin of 30.99% and a return on equity of 109.52%. The business’s quarterly revenue was up 42.6% on a year-over-year basis. During the same period in the prior year, the firm earned $5.32 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. On average, sell-side analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Eli Lilly and Company

Several hedge funds and other institutional investors have recently made changes to their positions in LLY. Laurel Wealth Advisors LLC increased its holdings in shares of Eli Lilly and Company by 78,621.2% during the second quarter. Laurel Wealth Advisors LLC now owns 11,552,336 shares of the company’s stock valued at $9,005,392,000 after acquiring an additional 11,537,661 shares in the last quarter. Norges Bank acquired a new position in Eli Lilly and Company during the 2nd quarter valued at approximately $8,827,714,000. Capital Research Global Investors raised its holdings in shares of Eli Lilly and Company by 20.9% in the third quarter. Capital Research Global Investors now owns 25,088,371 shares of the company’s stock worth $19,141,787,000 after buying an additional 4,332,008 shares during the last quarter. Vanguard Group Inc. lifted its stake in shares of Eli Lilly and Company by 1.5% during the second quarter. Vanguard Group Inc. now owns 80,407,430 shares of the company’s stock worth $62,680,004,000 after buying an additional 1,183,038 shares during the period. Finally, Amundi grew its holdings in shares of Eli Lilly and Company by 27.1% during the third quarter. Amundi now owns 4,525,902 shares of the company’s stock valued at $3,823,977,000 after buying an additional 964,675 shares during the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Q4 beat and strong 2026 outlook — Lilly topped revenue and EPS estimates on surging sales of Mounjaro and Zepbound and gave upbeat 2026 guidance that underpinned the recent rally. Eli Lilly Beats Q4 Estimates But Shares Slide
• Positive Sentiment: Analysts remain constructive — at least one analyst kept an outperform rating and raised the price target (to $1,300), signaling continued confidence in Lilly’s multi‑year growth runway. Eli Lilly Beats Q4 Estimates But Shares Slide
• Positive Sentiment: Execution and capacity expansion support volume growth — MarketBeat’s sector coverage highlights Lilly’s manufacturing build‑out and vial strategy that helped offset U.S. pricing pressure by driving a big volume increase. The Metabolic Split: Why Eli Lilly Soars as Novo Stumbles
• Neutral Sentiment: Ongoing capital investment — Lilly announced sizable new manufacturing spending (e.g., a $3.5B Pennsylvania facility), which supports longer‑term supply but is near‑term capex intensive. Eli Lilly to Invest Over $3.5 Billion in New Manufacturing Facility
• Neutral Sentiment: Pipeline and M&A activity diversify long‑term upside — deals (e.g., hearing‑loss and other collaborations) broaden optionality beyond GLP‑1s but will take time to materialize. Eli Lilly Is Getting Into the Hearing Loss Market
• Negative Sentiment: New low‑price competitor copy accelerates pricing fears — telehealth firm Hims & Hers announced a $49 copy of Wegovy, stoking concerns that cheaper entrants and pricing pressure could erode margins and force faster price competition across the GLP‑1 category. That news is a near‑term catalyst for the pullback. Novo Nordisk and Eli Lilly fall after Hims & Hers announce $49 copy of Wegovy pill
• Negative Sentiment: Profit‑taking and volatility after a huge run — after the stock surged on the beat and guidance (reclaiming ~$1T market cap), some investors are locking gains; analysts and outlets warn a pullback is possible given the stock’s run and valuation sensitivity to GLP‑1 pricing assumptions. Why Eli Lilly Stock Just Dropped

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.